AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12840625 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC; N = 7)
Number of subjects: 13
Study 12840625 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CON; N = 6)
Number of subjects: 13
Study 10488604 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous puncture (P group)
Number of subjects: 70
Study 10488604 — intervention group
Group type: COMPARATOR
Intervention: Alcohol swab friction (F group)
Number of subjects: 70
Study 10488604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 8829938 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 64
Study 8829938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 64
Study 8829938 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine
Number of subjects: 64
Study 2052631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐ES group (electrical stimulation applied to four antihypertensive acupuncture points)
Number of subjects: 10
Study 2052631 — intervention group
Group type: COMPARATOR
Intervention: Sham‐ES group (electrical stimulation applied to non‐acupuncture‐point areas)
Number of subjects: 10
Study 6315775 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate-receptor antagonist)
Number of subjects: 8
Study 6315775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31103481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 130
Study 31103481 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130
Study 29575717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (terbinafine, fluconazole, itraconazole, voriconazole, or posaconazole) for 4 to >12 weeks with standard bronchodilator and anti-inflammatory agents
Number of subjects: 41
Study 29575717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy
Number of subjects: 41
Study 29575717 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without antifungals
Number of subjects: 41
Study 26223423 — intervention group
Group type: COMPARATOR
Intervention: SLActive Bone level implant (Institut Straumann AG, Basel, Switzerland)
Number of subjects: 30
Study 26223423 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI IS‐II active implant (Neobiotech Co., Seoul, Korea)
Number of subjects: 30
Study 23657668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance (MRA) with minimal coverage of teeth and palate
Number of subjects: 24
Study 23657668 — intervention group
Group type: COMPARATOR
Intervention: Mandibular repositioning appliance (MRA) with greater acrylic resin bulk and interocclusal contact
Number of subjects: 24
Study 23657668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MRAs
Number of subjects: 24
Study 22764291 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 780
Study 22764291 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate plus amodiaquine (AS+AQ)
Number of subjects: 780
Study 22764291 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 780
Study 20614571 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200 (6% hydroxyethyl starch 200/0.5)
Number of subjects: 35
Study 20614571 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130 (6% hydroxyethyl starch 130/0.4)
Number of subjects: 35
Study 20614571 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers)
Number of subjects: 35
Study 17602086 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1,000 mg/m2 (days 1 and 8; every 21 days)
Number of subjects: 195
Study 17602086 — intervention group
Group type: COMPARATOR
Intervention: PLD 50 mg/m2 (day 1; every 28 days)
Number of subjects: 195
Study 17602086 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 195
Study 17602086 — intervention group
Group type: COMPARATOR
Intervention: PLD
Number of subjects: 195
Study 14996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine prophylaxis
Number of subjects: 18
Study 14996349 — intervention group
Group type: COMPARATOR
Intervention: Control (no lamivudine therapy)
Number of subjects: 18
Study 11831309 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100 and Scotchbond Multi‐Purpose (SBMP) restorative system
Number of subjects: 726
Study 9509971 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF started on day 0
Number of subjects: 70
Study 9509971 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF started on day +3
Number of subjects: 70
Study 9509971 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF started on day +5
Number of subjects: 70
Study 7800170 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg perazine
Number of subjects: 20
Study 7800170 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated
Number of subjects: 20
Study 2784382 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 0.60 ppm NO2 (n = 9)
Number of subjects: 24
Study 2784382 — intervention group
Group type: EXPERIMENTAL
Intervention: Background 0.05 ppm NO2 with three 15‐min peaks of 2.0 ppm (n = 15)
Number of subjects: 24
Study 2784382 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control group)
Number of subjects: 24
Study 1159128 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural training (3 sessions of behavior rehearsal, modeling, and coaching)
Number of subjects: 0
Study 1159128 — intervention group
Group type: COMPARATOR
Intervention: Assessment control group
Number of subjects: 0
Study 31941527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test (FIT) kits
Number of subjects: 0
Study 31941527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mailed FIT kits)
Number of subjects: 0
Study 31941527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT intervention for persons of Asian descent
Number of subjects: 0
Study 31975520 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional regulation training
Number of subjects: 60
Study 31975520 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 30352894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 833
Study 30352894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 833
Study 30352894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study 27073832 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) therapy, 15 minutes of intermittent vibration, performed twice per week for three months.
Number of subjects: 31
Study 27073832 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), continued normal activities.
Number of subjects: 31
Study 25529351 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 40
Study 25529351 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 40
Study 22717796 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal video‐assisted cholecystectomy (TVC)
Number of subjects: 128
Study 22717796 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 128
Study 20363089 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of Addiction to Nicotine in Schizophrenia (TANS)
Number of subjects: 87
Study 20363089 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management (MM)
Number of subjects: 87
Study 20363089 — intervention group
Group type: COMPARATOR
Intervention: Both TANS and MM
Number of subjects: 87
Study 18766258 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGLip‐rFVIII‐FS reconstituted with 4.2 mg/kg of pegylated liposomes
Number of subjects: 16
Study 18766258 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGLip‐rFVIII‐FS reconstituted with 12.6 mg/kg of pegylated liposomes
Number of subjects: 16
Study 18766258 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGLip‐rFVIII‐FS reconstituted with 22.1 mg/kg of pegylated liposomes
Number of subjects: 16
Study 18766258 — intervention group
Group type: COMPARATOR
Intervention: rFVIII‐FS (control)
Number of subjects: 16
Study 15998278 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment with adjunctive doxycycline (100 mg/day for 15 days)
Number of subjects: 60
Study 15998278 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment without doxycycline
Number of subjects: 60
Study 12706919 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) >80 pg/ml
Number of subjects: 1676
Study 12706919 — intervention group
Group type: COMPARATOR
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 1676
Study 11741217 — intervention group
Group type: EXPERIMENTAL
Intervention: nucleoside + lamivudine + nevirapine
Number of subjects: 100
Study 11741217 — intervention group
Group type: COMPARATOR
Intervention: nucleoside + lamivudine + cotrimoxazole
Number of subjects: 100
Study 8829881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum voluntary eccentric muscle actions
Number of subjects: 30
Study 8829881 — intervention group
Group type: COMPARATOR
Intervention: Superimposed electrical stimulation
Number of subjects: 30
Study 8829881 — intervention group
Group type: COMPARATOR
Intervention: Measures of arm circumference and ability to fully flex the elbow
Number of subjects: 30
Study 1944976 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anti-platelet therapy with ASA and dipyridamole
Number of subjects: 15
Study 1944976 — intervention group
Group type: COMPARATOR
Intervention: Postoperative anti-platelet therapy with indobufene
Number of subjects: 15
Study 6365463 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 50
Study 6365463 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 50
Study 31868691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified nonverbal facilitation of swallowing
Number of subjects: 10
Study 31868691 — intervention group
Group type: COMPARATOR
Intervention: Basic care of the face and mouth plus treatment as usual
Number of subjects: 10
Study 28586638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg, Ibuprofen 400 mg, Codeine 60 mg
Number of subjects: 131
Study 28586638 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1,000 mg, Ibuprofen 400 mg
Number of subjects: 131
Study 27117850 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 kcal meal (extremely hypocaloric)
Number of subjects: 10
Study 27117850 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 kcal meal (moderately hypocaloric)
Number of subjects: 10
Study 27117850 — intervention group
Group type: COMPARATOR
Intervention: 800 kcal meal (normocaloric)
Number of subjects: 10
Study 24569618 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily for 12 weeks
Number of subjects: 42
Study 24569618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 12 weeks
Number of subjects: 42
Study 24569618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22947332 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter with £45 vouchers for receiving three vaccinations
Number of subjects: 1000
Study 22947332 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination invitation letter
Number of subjects: 1000
Study 19249034 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous endometrial coculture during ART cycles
Number of subjects: 68
Study 19249034 — intervention group
Group type: COMPARATOR
Intervention: Conventional ART cycles
Number of subjects: 68
Study 17055685 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin mesylate (4 mg single dose)
Number of subjects: 12
Study 15727589 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nasal filters
Number of subjects: 46
Study 15727589 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal filters
Number of subjects: 46
Study 12173810 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia plus temporary, intraoperative intercostal nerve blockade using 0.25% bupivacaine (group B)
Number of subjects: 40
Study 12173810 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia only (group A)
Number of subjects: 40
Study 9698717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg single-dose treatment
Number of subjects: 96
Study 9698717 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 400 mg single-dose treatment
Number of subjects: 96
Study 8550163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated functional brace
Number of subjects: 85
Study 8550163 — intervention group
Group type: COMPARATOR
Intervention: Conventional plaster treatment
Number of subjects: 85
Study 3328986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (40 mg daily for 2 years)
Number of subjects: 1407
Study 29795665 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate-Pain-Reporting-Training (APRT)
Number of subjects: 51
Study 29795665 — intervention group
Group type: COMPARATOR
Intervention: No-Training (Control)
Number of subjects: 51
Study 27418444 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate
Number of subjects: 754
Study 27418444 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for nonresponse to 17-alpha hydroxyprogesterone caproate
Number of subjects: 754
Study 24034864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental hygiene care programme using flash-based video, brochures, and toothpick method
Number of subjects: 73
Study 22850734 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 25
Study 22850734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20889882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 468
Study 20889882 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 468
Study 20889882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) among breastfeeding children
Number of subjects: 468
Study 20889882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) among non-breastfeeding children
Number of subjects: 468
Study 20889882 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 18 months (independent of treatment)
Number of subjects: 468
Study 18950305 — intervention group
Group type: EXPERIMENTAL
Intervention: AC on (automatic capture)
Number of subjects: 910
Study 18950305 — intervention group
Group type: COMPARATOR
Intervention: AC off (standard programming)
Number of subjects: 910
Study 18950305 — intervention group
Group type: EXPERIMENTAL
Intervention: AC on
Number of subjects: 910
Study 19439966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 g omega-3 fatty acids daily for 6 months
Number of subjects: 35
Study 19439966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15057894 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine plus UDCA
Number of subjects: 85
Study 15057894 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus UDCA
Number of subjects: 85
Study 11694151 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy (n = 1222)
Number of subjects: 3489
Study 11694151 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment strategy (n = 1235)
Number of subjects: 3489
Study 11694151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1127)
Number of subjects: 3489
Study 11694151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (n = 1140)
Number of subjects: 3489
Study 9414055 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 45
Study 9414055 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 45
Study 8275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine (chlorpromazine 350 mg)
Number of subjects: 30
Study 8275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrophenone (haloperidol 15 mg)
Number of subjects: 30
Study 8275889 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 30 mg/day
Number of subjects: 30
Study 8275889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8275889 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic agents (trihexiphenidyl, 5 mg)
Number of subjects: 30
Study 2827044 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 16
Study 2827044 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (120 mg twice daily)
Number of subjects: 16
Study 11257242 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG-OC
Number of subjects: 66
Study 11257242 — intervention group
Group type: COMPARATOR
Intervention: LNG-OC
Number of subjects: 66
Study 31077604 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with dogs
Number of subjects: 1124
Study 31077604 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional dog owned
Number of subjects: 1124
Study 31077604 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants living with at least two dogs
Number of subjects: 1124
Study 31077604 — intervention group
Group type: COMPARATOR
Intervention: Owning dogs or cats
Number of subjects: 1124
Study 29072362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 214
Study 29072362 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led care (RLC)
Number of subjects: 214
Study 26998961 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-to-goal instruction
Number of subjects: 120
Study 26998961 — intervention group
Group type: COMPARATOR
Intervention: Brief verbal instruction
Number of subjects: 120
Study 25012432 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 32
Study 25012432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22743314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (20 g/d, 3 times/d for 4 weeks)
Number of subjects: 32
Study 22743314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times/d for 4 weeks)
Number of subjects: 32
Study 22743314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 32
Study 22743314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19647945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg)
Number of subjects: 20
Study 19647945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17373724 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of caffeine per day
Number of subjects: 0
Study 17373724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine withdrawal for 2 weeks
Number of subjects: 0
Study 17373724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 14694237 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation with vitamins C and E
Number of subjects: 158
Study 14694237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 12382087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% octenidine dihydrochloride with 30% 1‐propanol and 45% 2‐propanol
Number of subjects: 60
Study 12382087 — intervention group
Group type: COMPARATOR
Intervention: 74% ethanol with 10% 2‐propanol
Number of subjects: 60
Study 9689291 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler Imaging (LDI)
Number of subjects: 0
Study 9689291 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive dependency posture
Number of subjects: 0
Study 9689291 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of methyl nicotinate (vasodilator)
Number of subjects: 0
Study 8136665 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 1255
Study 8136665 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 1255
Study 8136665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinard stethoscope by research midwife
Number of subjects: 1255
Study 8136665 — intervention group
Group type: COMPARATOR
Intervention: Routine use of Pinard stethoscope by attending midwife
Number of subjects: 1255
Study 2686425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (200 mg every 12 hours, plus a daily extra placebo dose)
Number of subjects: 59
Study 2686425 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime (1 g every eight hours)
Number of subjects: 59
Study 2686425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 59
Study 2686425 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime
Number of subjects: 59
Study 2686425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study 30266711 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 pedicle screw with PMMA augmentation (group A)
Number of subjects: 75
Study 30266711 — intervention group
Group type: COMPARATOR
Intervention: S1 bicortical pedicle screw fixation (group B)
Number of subjects: 75
Study 30266711 — intervention group
Group type: COMPARATOR
Intervention: S1 tricortical pedicle screw fixation (group C)
Number of subjects: 75
Study 28225052 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification and nutritional education (BM-NE) intervention
Number of subjects: 139
Study 28225052 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 139
Study 25925801 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention ('breakingtheice')
Number of subjects: 160
Study 25925801 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 160
Study 23270788 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial portal technique (AMP)
Number of subjects: 50
Study 23270788 — intervention group
Group type: COMPARATOR
Intervention: Transtibial technique
Number of subjects: 50
Study 21205384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex+PLA)
Number of subjects: 100